Parkinson's disease (PD) is the second most common neurodegenerative disorder with a prevalence of 3% in individuals older than 65 years of age. 1 Although the majority of PD 60 cases are sporadic, it is now clear that genetic factors contribute to the pathogenesis of PD.
Indeed, alpha-synuclein, 2 UCH-L1, 3 and LRRK2 4, 5 have been reported as causative genes of autosomal dominant PD (ADPD); and parkin, 6 DJ-1, 7 and PINK1 8 as causative genes of autosomal recessive PD (ARPD). Recently, LRRK2 was identified as the causative gene for PARK8, 4 ,5 and a common single LRRK2 mutation in exon 41 (G2019S) has been found in 65 mainly Caucasian patients with familial PD. 9 In the present study, we performed direct sequencing of LRRK2 exon 41 in a large number of patients with familial and sporadic PD of different ethnic origins. We also analyzed the haplotype to determine whether a single haplotype was associated with LRRK2 mutations. In addition, we investigated the clinicogenetic features, including cardiac 123 I-metaiodobenzylguanidine (MIBG) scintigraphy, 70 of patients with LRRK2 mutations.
Patients and Methods
All blood samples and clinical information were obtained by the neurologists working in the 75 respective countries after obtaining informed consent from their patients. The study was approved by the ethics review committee of Juntendo University. Diagnosis of PD was made by the participating neurologists based on the presence of parkinsonism, good response to anti-PD treatment, and radiological findings. In all countries, the clinical evaluation was based on the Unified Parkinson's Disease Rating Scale. Controls were evaluated by 80 neurologists to ensure none of them had PD. For control subjects, the mean age of the Japanese was 56.1 (range, 23-98) years and that of the Taiwanese was 34.4 (range, years. DNA was prepared using standard methods. The mutation screening was performed as 
Results
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Genetic studies
We found two heterozygous missense mutations (6059T>C; I2020T and 6055G>A; G2019S), which had been reported previously, 5,9, 12-14 and one novel heterozygous missense mutation (6035T>C; I2012T) ( Fig. 1a, b) . The novel I2012T mutation is also highly conserved across various species, similar to the other previously reported mutation sites of I2020T and Asian people. In addition to the pathogenic mutations, we found a novel single polymorphism (6054C>T) that was synonymous (Y2018Y) in two Korean families.
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The parent and the parent's sibling of Japanese Patients J1 and J2 with the I2020T
were born in the Sagamihara area, and the Japanese Patient K1 with the I2020T was also born near the Sagamihara area. The haplotype with five microsatellite markers in this region was 140 exactly the same as that of the Sagamihara family. 11, 12 In contrast, the haplotype of the other Japanese Family B (Patients B1 and B2) with the G2019S was quite different from that of the Caucasian families reported previously (Fig. 2a, b) . The doses of anti-PD drugs for Patient J2 were selegiline 2.5 mg/day, cabergoline 3 mg/day, amantadine 150 mg/day, and talipexole 1.2 mg/day. Patient B1 developed upward gaze palsy.
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None of the patients showed severe autonomic disturbances or amyotrophy. The age at onset of the patients with these three mutations varied widely from 37 to 73 years (average, 55.0 years). In addition to these patients, two grown-up children (aged 36 and 38 years) with mutations were asymptomatic (Family C, Fig. 1b) . Pathologic studies could not be conducted in all patients with LRRK2 mutations in this study.
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Cardiac MIBG scintigraphy was performed in Patients B1 and B2 with G2019S mutation and Patients J1, J2, and K1 with I2020T mutation (Table) . For Patient B1, B2, and 
Discussion
The present study revealed that the LRRK2 G2019S mutation spreads worldwide across different ethnic groups with variable frequencies. Whereas the G2019S mutation is quite rare 175 in Asia, this mutation is more frequent around Europe 9,13,14 and especially in North Africa.
Demographically, it is possible that the distribution and frequencies of this mutation is associated with human migration history. In a previous report, European and North American patients with the G2019S shared a common ancestral haplotype indicative of a single founder effect. 10 Indeed, our patients from around Europe and North Africa also had the same 180 haplotype. On the other hand, the haplotype of Japanese Family B was quite different from that of Caucasian patients, suggesting they do not share a common founder and they are of independent origin. The possibility that Japanese patients have a common haplotype on the very narrow region could not be excluded. However, it is unlikely that the Japanese G2019S mutation originated from a common and extremely old founder, because the G2019S 185 mutation is rare in Asian people compared with North African and Caucasian peoples. With regard to the mode of inheritance, our study showed that not only patients with ADPD but also those with potential ARPD and sporadic PD had LRRK2 mutations. Moreover, 200 we detected the mutations in late-and early-onset PD. A shared LRRK2 G2019S haplotype in the vast majority of carriers argues against de novo occurrence. 13 Based on the widely variable age at onset and various modes of inheritance, the phenotype of PD patients with LRRK2 mutations must be influenced by stochastic, environmental, and other genetic factors.
PARK8 was originally mapped from Japanese Sagamihara family showing late-onset
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The clinical features of most patients with LRRK2 mutations resemble those of patients with typical idiopathic PD.
10 Previously reported patients with LRRK2 mutations, especially those with G2019S and I2020T, showed no evidence of psychiatric or cognitive dysfunction apart from mild symptoms, despite the long disease duration. In the present study, the clinical features and cardiac uptake of MIBG varied even in 235 patients with the same I2020T mutation, and also even in members of the same family.
Indeed, one PD patient with the I2020T mutation from the Sagamihara family had Lewy In the previously reported German-Canadian family and Western Nebraska family, the phenotypes of PARK8-linked parkinsonism with signs of dementia, diffuse Lewy body disease (DLBD), progressive supranuclear palsy (PSP), and motor neuron degeneration, showed pathological features of synucleinopathies and tauopathies. [24] [25] [26] [27] In the present study, one patient with G2019S showed upward gaze palsy like PSP although downward gaze palsy product. 28 Furthermore, this protein may be potentially associated with phosphorylation of both alpha-synuclein and tau. 4, 5, 29 Indeed, concurrent pathology of alpha-synuclein and tau accumulation within the same aggregates was reported previously. 29 Therefore, the kinase activity of the LRRK2 product could be a key event in the accumulation and aggregation of 260 these unfolded proteins within the degenerating neurons, 4, 5 and could be an upstream event.
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